Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
Anemia of Chronic Kidney Disease, Endothelial Dysfunction, Left Ventricular Hypertrophy
About this trial
This is an interventional diagnostic trial for Anemia of Chronic Kidney Disease
Eligibility Criteria
Inclusion Criteria:
All patients:
- Above 18 years old
- Diagnosed as CKD, and renal transplanted patients at Assiut University Hospital in the period 2017-2020 .
Exclusion Criteria:
- Severely hypocalcaemic patients < 7mg/dl.
- Severely hyperphosphatemic patients >7 mg/dl .
- Uncontrolled hypertensive patients ( more than 3 antihypertensive drugs).
- Uncontrolled diabetic patients HBA1C >8 .
- Blood transfusion dependent
Sites / Locations
- Assiut University Hospitals
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
CKD patients with different stages
Newly renal transplanted patients .
Full clinical history and through clinical examination. Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents. Iron study at time of diagnosis and 3 months after treatment . Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually. 6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation .
Full clinical history and through clinical examination. Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years. Pre-transplant full blood count serial measures every / 3 months for 2 years. Pre transplant serum Iron study and annually for 2 years. 24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually. Post-transplant serum FGF-23 (as independent risk factor) at 6months. Different immunosuppressive protocols. Pre-transplant panel reactive antibody,donor-specific antibody